No Prescription |
 |
 | ||
|
Refzil O Cefzil |
|
| ||
No Prescription » Prescription Drugs 14 » Refzil O Cefzil Cefprozil is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for viral infections (e.g. common cold flu). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.How to use Cefprozil OralTake this medication by mouth usually once or twice daily or as directed by your doctor. You may take this medicine with food if stomach upset occurs. Dosage is based on your medical condition and response to therapy. In children the dosage is also based on weight.Antibiotics work best when the amount of medicine in your body is kept at a constant level. Therefore take this drug at evenly spaced intervals.Continue to take this medication until the full-prescribed amount is finished even if symptoms disappear after a few days. Stopping the medication too early may allow bacteria to continue to grow which may result in a relapse of the infection.Cefprozil Oral is used to treat the following:Strep Throat Strep Throat and Tonsillitis Infection of the Middle Ear by H. Influenzae Bacteria Infection of the Middle Ear caused by Streptococcus Middle Ear Infection caused by Moraxella Catarrhalis Infection of the Middle Ear by S. Pneumoniae Bacteria Middle Ear Infection Acute Bacterial Infection of the Sinuses Severe Sinusitis caused by Streptococcus Pneumoniae Severe Sinusitis caused by Haemophilus Influenzae Severe Sinusitis caused by Moraxella Catarrhalis Inflammation of the Tonsils Acute Infection of the Nose Throat or Sinus Bronchitis Bacterial Infection with Bronchitis Bronchitis caused by the Bacteria Streptococcus Pneumoniae Bronchitis caused by the Bacteria Haemophilus Influenzae Bronchitis caused by the Bacteria Moraxella Catarrhalis Bacterial Infection with Chronic Bronchitis Chronic Bronchitis caused by Streptococcus Pneumoniae Chronic Bronchitis caused by Haemophilus Influenzae Chronic Bronchitis caused by Moraxella Catarrhalis Skin Infection Skin Infection due to Staphylococcus Aureus Bacteria Skin Infection due to Streptococcus Pyogenes BacteriaCefprozil Oral may also be used to treat:Pediatric Fever without a Source Buy Refzil O Cefzil and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About Refzil O Cefzil: Product Type: Prescription Drugs 14 Refzil-O ( Cefzil Generic Cefprozil ) Refzil-O (Cefzil Generic Cefprozil) Cefzil Generic Cefprozil 250mg 30 Tablets 250mg 2 x 30 Tablets 500mg 3 x 30 Tablets 500mg 30 Tablets 500mg 2 x 30 Tablets Cefzil Generic Cefprozil Refzil-O
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
